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Abstract
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The role of genetics in the pathogenesis of necrotizing enterocolitis (NEC) was initially informed
by epidemiological data indicating differences in prevalence among different ethnic groups as well
as concordance in twins. These early observations, together with major advances in genomic
research, paved the way for studies that begin to reveal the contribution of genetics to NEC. Using
the candidate gene- or pathway approach, several potential pathogenic variants for NEC in
premature infants have already been identified. More recently, exome- and genome-wide
association study for NEC has also been completed. These advances, however, are tempered by the
lack of adequately powered replication cohorts to validate the accuracy of these discoveries.
Despite many challenges, genetic research in NEC is expected to increase, providing new insights
into its pathogenesis and bringing the promise of personalized care closer to reality. In this review
we provide a summary of genetic studies in NEC along with defining the challenges and possible
future approaches.

INTRODUCTION

Author Manuscript

Necrotizing enterocolitis (NEC) is a devastating inflammatory disease of the preterm
intestinal tract that afflicts 5 to 10% of infants weighing less than 1500 grams at birth.1
Despite considerable advances in neonatal medicine, outcomes for NEC have remained
stagnant and may even be worsening.2, 3 Many risk factors – such as formula feeds,
infection, ischemia, and gut dysbiosis – have been implicated in NEC.4 Clinical risk factors
alone, however, cannot explain the inter-individual variability in NEC susceptibility or
severity in premature infants, indicating a role for inherited risk factors in disease
pathogenesis.5
Epidemiological studies were the first to provide clues regarding a genetic contribution to
NEC. Risk for NEC varied widely based on ethnic distribution, occurring less frequently in
Japan, Switzerland, and Austria while afflicting preterm infants more often in North
America, United Kingdom, and Ireland.4 Although this variation could be due to differences
in local neonatal care strategies, studies limited to the United States also demonstrated
differences in risk based on race, with African American infants more likely to develop NEC
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than Caucasians.6, 7 Twin studies by Bhandari et al.5 also demonstrated that more than 50%
of variance in NEC is accounted for by genetic and shared environmental factors. These
studies triggered investigations by several researchers into the genetic basis of NEC risk.
Advances in our understanding of the genetic basis of complex diseases, combined with
technological advances in genotyping platforms, are beginning to yield promising, if
preliminary results. In this review, we (1) summarize current genetic studies in NEC, (2)
discuss various challenges and limitations of these studies, and (3) discuss future approaches
for identifying pathogenic loci for NEC.

CANDIDATE GENE APPROACH

Author Manuscript

The candidate gene approach has been used in majority of the genetic studies of NEC. In
this approach, investigators evaluate single nucleotide polymorphisms (SNPs) of a few, preselected genes based on a priori hypothesis of relevance to NEC. The discussion that
follows, along with Table 1 and Figure 1, summarize candidate genes for NEC that have
been evaluated using this approach, with an emphasis on understanding the biological
relevance of the gene or pathway to NEC development.
Toll-like receptors (TLR)

Author Manuscript

TLRs are pattern recognition receptors (PRR) that recognize conserved structural motifs in
pathogens and activate innate immune responses. TLR4, which is important for immunity
against Gram-negative bacteria, has been implicated in NEC by studies showing elevated
expression in intestinal samples obtained from NEC infants.31 Experimental studies in
rodents also demonstrated an obligatory role for TLR4 in NEC, further highlighting its
importance in its pathogenesis.32, 33 Preliminary genetic studies in humans, however, have
yet to yield strong evidence that genetic variations in TLR pathway increases susceptibility
to NEC. In a cohort of 270 preterm infants, Sampath et al.9 did not find an association
between NEC and SNPs in TLR receptors and TLR pathway mediators. Szebani et al.8 also
did not find any association between NEC and SNPs in TLR4 and cluster of differentiation
14 (CD14, a key co-receptor of TLR4). In another study, Zhou et al.10 investigated myeloid
differentiation-2 (MD2, another co-receptor of TLR4) in 42 NEC cases and 83 controls.
Overall, there was no difference in the frequency of MD2 SNPs between NEC cases and
controls; although analysis based on severity demonstrated a small but significant increased
risk of surgical NEC with MD2 variants (OR 1.66, 95% CI 1.09–3.05, p=0.036).
Single immunoglobulin and toll-interleukin 1 receptor (SIGIRR)

Author Manuscript

Using whole exome sequencing (WES), Sampath et al.11 identified a novel stop variant
(p.Y168X) of SIGIRR in an infant with NEC totalis. Additional Sanger sequencing of the
SIGIRR gene in 37 other preterm infants (17 with NEC) demonstrated that rare and novel
variants of SIGIRR were enriched in preterm infants with NEC compared to controls, further
implicating SIGIRR as a candidate gene for NEC. Functional studies in intestinal epithelial
cells showed that the identified variants were functional mutations that led to loss of SIGIRR
function, dysregulated TLR activation, and excessive inflammation. Additional in-vivo
studies using SIGIRR−/− mice confirmed that loss of SIGIRR function results in a
phenotype of exaggerated intestinal inflammation and increased NEC susceptibility
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compared to controls.34 Intriguingly, SIGGIR functions as a “brake” to prevent excessive
TLR activation and inflammation in the intestines.35 Thus, although no genes that mediate
TLR signaling have been strongly associated with NEC, inhibitors of TLR signaling (such as
SIGIRR) may be promising NEC candidate genes.
Nucleotide binding oligomerization domain containing protein 2 (NOD2)

Author Manuscript

NOD2 is another PRR that recognizes the muramyl dipeptide component of bacterial cell
wall and interacts with autophagy pathways to target and degrade invading bacteria.36
Functional polymorphisms in NOD2, which are strongly implicated in inflammatory bowel
disease, have been hypothesized to also be important in NEC.37 In a preliminary study,
Zouali et al.12 sequenced the entire NOD2 gene of 10 preterm infants with NEC but found
no novel NOD2 variants associated with NEC. Szebani et al.8 also found no evidence of
association between SNPs of NOD2 and NEC in their study of 118 preterm infants, 41 of
whom had NEC. Similar findings of no association was found by Sampath et al.14 between
NOD1 or NOD2 variants and NEC in a large, multi-center study involving 1015 preterm
infants. In an even larger study, Härtel et al.13 genotyped more than 9,000 preterm infants of
European ancestry and found that while no single NOD2 variant was associated with NEC,
presence of 2 or more loss of function NOD2 variants was significantly associated with an
increased risk for NEC (OR 4.14, 95% CI 1.41–12.12, P=0.009). Thus, while initial studies
were negative, the largest study seem to suggest that NOD2 variants do confer increased
NEC risk in premature infants.
Autophagy-related 16-Like 1 (ATG16L1)

Author Manuscript

ATG16L1 is essential for the proper assembly of lysosomes used in the autophagy of
invading pathogens. Induction of autophagy is associated with worse injury in experimental
NEC, while diminished autophagy decreases NEC.38 Sampath et al.14 evaluated the key
autophagy gene, ATG16L1, and found that a common ATG16L1 variant (Thr300Ala)
conferred protection against NEC (OR=0.4, 95% CI 0.19–0.81). This variant, which
increases sensitization of ATG16L1 to caspase-3-mediated degradation, results in
diminished autophagy and is thus consistent with prior studies showing protective role of
deceased autophagy against NEC. An independent replication cohort (260 infants, 23 with
NEC) also showed a trend towards decreased NEC among infants who were homozygous for
the loss of function variant allele, providing further evidence for the importance of this gene
in NEC.14 Further studies are needed to evaluate the role of this and other autophagy-related
genes in NEC.
Mannose binding lectin (MBL)

Author Manuscript

MBL is a circulating PRR that recognizes unique carbohydrate components of invading
pathogens and induces their phagocytic clearance by the complement system.39 Elevated
MBL levels are found in intestinal tract of preterm infants with NEC, suggesting that
excessive MBL activation may play a role in its pathogenesis.40 Prencipe et al.15 evaluated
107 preterm infants (41 with NEC) for SNPs of MBL and found that a promoter SNP (−221
X/Y) of the MBL gene was more common in infants with NEC (OR 4.42, 95% CI 1.11%
−17.49%, p=0.03). This polymorphism is associated with increased serum MBL levels,

Semin Fetal Neonatal Med. Author manuscript; available in PMC 2019 December 01.

Cuna et al.

Page 4

Author Manuscript

supporting the hypothesis that gain of function variants of MBL is associated with an
increased risk for NEC.
Platelet activating factor (PAF)

Author Manuscript

PAF is an endogenous phospholipid with potent pro-inflammatory actions.41 Infants with
NEC have increased plasma levels of PAF, and administration of intravenous PAF in animal
models induces NEC.42 Conversely, PAFAH – an enzyme that degrades PAF – has decreased
activity and concentration in infants with NEC, and enteral administration of recombinant
PAFAH in animal models results in a significant decrease in NEC.43, 44 Sankararaman et al.
16 evaluated the role of functional PAFAH polymorphisms in a convenience cohort of 570
preterm infants (36 with stage 1 or 2 NEC, 534 without NEC) and found no evidence of
association between PAFAH SNPs and NEC. In contrast, Zhou et al.10 evaluated SNPs of
GM2 activator protein (GM2A), which is another PAF antagonist, in a Chinese cohort of 125
infants (42 with NEC) and found a positive association between NEC and 2 variants of
GM2A – rs1048719 (OR 1.86, 95% CI 1.04–3.33) and rs2075783 (OR 3.23, 95% CI 1.69–
6.21). Inclusion of term infants in this study, however, makes it difficult to determine
whether the differences detected were due to prematurity or NEC.
Nuclear factor-kappa B (NFKB)

Author Manuscript

NFKB is a major transcription factor that regulates the expression of several proinflammatory genes.45 NF-κB levels are increased in the intestines following NEC induction
in rats, while inhibiting NFKB protects against excessive inflammation.46, 47 Sampath et al.9
studied NFKB in NEC and found that the NFKB1 (g.−24519delATTG) variant was present
in all 15 infants with NEC compared to only 166 of 256 without NEC (100% vs 65%, OR
∞, 95% CI 2.1−∞, p=0.003), suggesting that this variant may be necessary, but not
sufficient, for developing NEC. On the other hand, the NFKBIA (g.1004A>G) variant was
less common in infants with NEC compared to infants without NEC (13.3% vs 49%, OR
0.16, 95% CI 0.04–0.60, P=0.007), suggesting that this variant may confer protection against
NEC.
Pro-inflammatory cytokines

Author Manuscript

As excessive inflammation is a hallmark of NEC, many investigators have examined the
relationship of several pro-inflammatory cytokine gene polymorphisms and NEC, with
varying results. Treszl et al.17, 18, Heninger et al.19, Henderson et al.20, and Szpecht et al.22
have examined functional variants of several pro-inflammatory cytokines (including tumor
necrosis factor-alpha, interleukin (IL)-1β, IL-4 receptor α-chain, IL-6, IL-18, and IL-10) and
found no evidence of association of these genes with NEC. In contrast, Franklin et al.21
reported a positive association between IL-6 (rs1800795) variant and NEC in Caucasian
neonates; while Tian et al.48 found a positive association between IL17F (rs763780) variant
and NEC in a Chinese cohort. Interestingly, the studies showing no association between proinflammatory cytokines and NEC comprised of neonates of European descent, suggesting
that ethnicity may play an important role on whether certain genetic variants contribute to
NEC or not.
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FUT2 mediates the inclusion of fucose sugar units to glycoproteins and glycolipids.
Polymorphisms in FUT2 gene, which result in differing phenotypes of secreted fucosylated
glycans on mucosal surfaces, have important implications in host-microbiome interactions.
Morrow et al.23 investigated non-secretor status (AA) of the FUT2 polymorphism (428G>A)
and found no evidence of association between this variant and NEC (OR 1.6, 95% CI 0.7–
3.8) or surgical NEC (OR 2.3, 95% CI 0.6–7.4). However, when salivary secretion of Hantigen was used to determine non-secretor status, a positive association with NEC was
found. Another study by Demmert et al.24 investigated the same FUT2 polymorphism
(248G>A) in a large prospective cohort of 2,406 VLBW infants and also found no
association of this polymorphism with NEC. These differential results can be possibly
explained by differences in FUT2 genotype and actual secretor phenotype, which has been
shown to not always be concordance likely because of epigenetic influences.

Author Manuscript

Genes regulating the antioxidant response
Anti-oxidants are important in alleviating injury from gut ischemia-reperfusion, and genetic
variants that limit anti-oxidant defenses can hypothetically increase risk of NEC in preterm
infants.49 Sampath et al.25 investigated loss of function SNPs in 6 anti-oxidant genes
belonging to the NF-E2-related factor 2-dependent antioxidant response elements (Nrf2ARE) pathway and found no evidence of association between the tested SNPs and NEC.
Another study by Huizing et al.26 looked at the C242T polymorphism of cytochrome B-245
alpha chain (a gene related to NADPH oxidase family) and also found no association of this
variant with NEC in a cohort of 451 preterm infants.
Vascular endothelial growth factor (VEGF)

Author Manuscript

Studies demonstrate that decreased intestinal expression of VEGF is seen in human NEC
compared to controls, suggesting that dysregulated VEGF signaling contributes to NEC
pathogenesis. Banyasz et al.29 evaluated VEGF polymorphisms in NEC and discovered that
a carrier state for VEGF-2578 mutant allele, which predisposes to low VEGF production, is
associated with an increased risk for NEC (OR 2.77, 95% CI 1.00–7.65, p=0.049). This is
consistent with studies in mice that demonstrate decreased VEGF signaling increases
susceptibility to NEC, while increased VEGF levels through subcutaneous administration
decreases the extent of mucosal injury in NEC.50, 51
Arginine and nitric oxide

Author Manuscript

Arginine is an important substrate for nitric oxide, which is a potent vasodilator that
regulates mucosal blood flow and helps maintain mucosal integrity. Low arginine levels have
been implicated in NEC based on observational studies demonstrating hypoarginemia in
preterm infants with NEC, and clinical trials showing decreased NEC in infants following
arginine supplementation.52, 53 Moonen et al.27 evaluated C-to-A nucleotide transversion
(T1405N) of carbamoyl-phosphate synthase (CPS), which is functionally correlated with
low plasma arginine levels, in a small study of 51 preterm infants (17 with NEC). They
found that the CC genotype was associated with increased NEC (unadjusted OR 3.43, 95%
CI 1.01–11.49), although this association was not significant once adjusted for gestational
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age and birth weight. As a follow-up to this study, Moonen et al.28 prospectively recruited
477 preterm infants from 4 different centers to investigate the same CPS1 polymorphism in
NEC. They again found no significant association between CC genotype and NEC. Instead,
a significant negative association was found between the minor A-allele and the combined
outcome of NEC or death, suggesting that the A-allele variant may confer protection against
NEC.

Author Manuscript

In another study, Szpecht et al.22 more directly evaluated nitric oxide pathways by
measuring polymorphisms of eNOS in 100 preterm infants, 22 of whom had NEC. They
found that eNOS 894G>T polymorphism was more common in infants with NEC (OR 20,
95% CI 3.71–208.7, p=0.0004), and the eNOS 786T>C was increased in infants with
surgical NEC (OR 4.88, 95% CI 1.33–21.99, p=0.013). Both variants have been associated
in other studies with impaired eNOS enzymatic activity, providing biological plausibility
that these variants are functional and potentially significant in NEC.54
Heparin-binding epidermal growth factor-like growth factor (HB-EGF)
HB-EGF has been shown in animal studies to promote repair of intestinal epithelial cells
resulting from various forms in injury in vitro, including in NEC.55 The protective role of
HB-EGF is thought to be mediated by increased intestinal blood flow, decreased apoptosis,
and increased enterocyte migration and proliferation.56 Ma et al.30 measured polymorphisms
of HB-EGF in 30 NEC patients and 80 controls and found that rs4912711 SNP was
associated with increased NEC. They also measured plasma levels of HB-EGF and found it
to be decreased in NEC infants with the rs4912711 SNP, providing additional evidence that
the identified SNP is potentially important.

Author Manuscript

GENOME-WIDE APPROACH
In genome-wide approach, millions of SNPs are evaluated in an unbiased manner, allowing
for discovery of previously unknown associations between genes and disease. Jilling et al.57
performed the first genome-wide association study (GWAS) in NEC in 751 extremely
preterm infants (30 with surgical NEC) and identified 35 SNPs significantly associated with
NEC. A cluster of SNPs in chromosome 8 (8q23.3) had the strongest association for NEC,
with odds ratio of 4.72 (95% CI 2.51–8.88). Other clusters of SNPs identified in
chromosome 14 and 11 also demonstrated significant association. A validation cohort did
not have sufficient power to replicate these findings, except for a single SNP found in
chromosome 8. Additional studies are required to confirm functional significance of the
identified SNPs. Further fine mapping or sequencing studies may also be necessary to
identify pathogenic genes or variants in identified clusters.

Author Manuscript

CHALLENGES AND LIMITATIONS
Several challenges and limitations can confound the results of genetic association studies,
especially for complex diseases such as NEC.58 The following discussion summarizes these
challenges as well as important considerations for performing robust genetic studies in NEC.
Table 2 characterizes the different genetic studies included in this review based on these
criteria.
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Studies should begin with precise phenotypic definition of NEC cases and controls. Only
confirmed cases of NEC in preterm infants (i.e. Bell’s Stage ≥ II) should be included.
Inclusion of term infants, spontaneous intestinal perforations (SIP), or unconfirmed NEC
(Bell Stage I) as NEC cases can limit the study’s power. Further confining to infants who
developed surgical NEC may confer additional precision to the phenotype. Ethnic
composition of the cohort should also be accurately described. Variant allele frequencies can
vary significantly by ethnicity, and false associations may arise because of population
admixture. In cohorts with mixed ethnicity, additional analysis of variants stratified by race
should be completed.

Author Manuscript

An adequate sample size is also key. Ideally, candidate genome approaches should include
hundreds of infants, while genome-wide approaches often need thousands of infants to attain
sufficient power. Such numbers are difficult to achieve for any disease, and is especially
difficult in NEC which variably afflicts about 5–10% of infants born preterm. Compounding
this challenge is the need to correct for multiple testing across the number of SNPs tested.
Given the challenges with sample size, only a handful of studies have been able to adjust for
multiple testing.

Author Manuscript

Separate validation cohorts are also important. In general, genetic association studies should
be treated as preliminary, hypothesis-generating studies until further validation has been
provided by subsequent replication cohorts. Given the challenge of obtaining adequate
sample size for discovery cohorts, few genetic studies in NEC have been replicated in
validation cohorts. Lastly, functional studies that explain the mechanisms underlying the
association of the gene with the disease are also important. Functional studies are
particularly important for genome-wide approaches such as GWAS and exome/whole
genome sequencing, where identified variants are likely of unknown significance to NEC
pathogenesis.

FUTURE CONSIDERATIONS
Advances in genetic research have allowed identification of many promising genes
associated with increased or decreased risk of NEC. Most of these studies, however, have
been limited by small sample sizes as well as lack of validation and functional studies.
Future efforts should be made to validate these candidate genes using independent
replication cohorts and functional studies. Although challenging to complete, such studies
are necessary to establish the importance of these genes and decrease risk of false discovery.

Author Manuscript

Future studies should also utilize unbiased genome-wide approaches, such as GWAS, WES,
or whole genome sequencing (WGS), to discover new genes and pathways. Linkage-based
approaches used in GWAS typically identify common variants (present in >1% of the
population) in intronic regions. Because of this, additional fine mapping/sequencing as well
as functional studies are typically needed to identify pathogenic genes and variants. In
contrast, WES directly identifies variants in the coding or exonic regions that are more likely
to have a functional impact on the gene product. WES is thus increasingly emerging as the
primary modality to query the genetic basis of complex diseases.59–61 WGS probes both
coding and non-coding regions of the genome.62 However, WGS encumbers very large
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samples sizes; and functional evaluation of regulatory variants found in non-coding regions
(i.e. introns, promoters, etc.) is still not fully developed.63 Thus, combining GWAS with fine
mapping, or alternatively WES directly, are suitable approaches to identify pathogenic loci
for NEC susceptibility.

Author Manuscript

Contribution of other “-omic” fields, which can be helpful in identifying genetic signatures
underlying NEC, should also be pursued. For example, Chan et al.64 performed
transcriptome (mRNA) sequencing of intestinal tissues from infants with surgical NEC
compared to controls and identified several dysregulated genes and pathways in NEC. Using
a similar strategy, Ng et al. 65 probed microRNAs (miR), a subset of small RNAs which are
not protein-coding but regulate other mRNAs, to identify regulatory pathways of interest in
NEC. Interestingly, both of these studies identified the TLR pathway as a key pathway
involved in NEC pathogenesis. This discovery, which further highlights the importance of
TLR in NEC, also provides evidence supporting the usefulness of this approach to identify
potential genetic pathways in NEC.
Finally, functional genomics approaches that combine genomics with transcriptome and
proteomics approaches may provide even deeper insights into understanding how pathogenic
genes direct molecular phenotypes that program NEC vulnerability.66–68 Major advances in
bioinformatics and network analysis provide platforms to interrogate and define the key
genetic pathways as well as molecular signatures that prime NEC vulnerability.

CONCLUSION

Author Manuscript

It is expected that genetic studies in NEC will continue to increase as technological advances
allow for more robust and less expensive exploration of the genome. Although a number of
potential gene variants have been identified, these discoveries have to be interpreted with
caution until further validation studies are completed. Future directions include use of whole
exome/genome sequencing to uncover novel and rare genes/variants in NEC.
Complimentary functional genomic approaches may also allow NEC prediction in premature
infants as well as defining pathways that may be targeted to prevent NEC. While these
exciting approaches hold significant promise for defining the molecular pathogenesis of
NEC and informing preventive approaches, they require collaborative approaches between
clinicians, researchers, and bioinformaticians for their success.
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External factors traditionally implicated in the pathogenesis of NEC include mucosal injury,
ischemia/reperfusion, aberrant microbial colonization, and immature immune system. In
addition, several candidate genes and pathways that may confer an inherent predisposition to
NEC are also increasingly being recognized. Red text = increased risk for NEC; green text =
protection against NEC.
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Table 1:

Author Manuscript

Summary of genes assessed using the candidate gene approach.
Gene/Pathway

Increased risk for NEC

TLRs8–10

MD2 (C-1625G)

SIGIRR11

SIGIRR (p.Y168X)
SIGIRR (p.S80Y)

Decreased risk for
NEC

No evidence of association with NEC
TLR2 (Arg753Gln)
TLR4 (Asp299Gly)
TLR4 Thr399Ile)
TLR4 (Asp299Gly)
TLR4 (Thr399Ile)
TLR5 (Arg392stop)
TLR9 (2849 C>T)
CD14 (−260 C>T)
IRAK1 (Leu532Ser)
TIRAP (Ser180Leu)

Author Manuscript

NOD2 (Gly908Arg)
NOD2 (R702W)
NOD2 (1007fs)
NOD2 (G908R)
NOD2 (rs2066844)
NOD1 (37684T>C)
NLRP3 (247617036G>T)
NLRP3 (247621033G>A)
NLRP3 (14384C>A)
CARD8 (26498T>A)

Autophagy8, 12–14

NOD2 (G908R)**
NOD2 (R702W)**
NOD2 (1007fs)**

MBL15

MBL2 (−221 G>C)

MBL2 (Codon 54 G>A) MBL2 (Codon 57 G>A)

PAF10, 16

GM2A (g.5220G>A)
GM2A (g.19168A>C)

PAFAH (Ile198Thr)
PAFAH (Ala379Val)

NFKB9

NFKB1(−24519delATTG)

Author Manuscript

Cytokines17–22

IL6(g.4880C>G)

ATG16L1(Thr300Ala)

NFKBIA(−1004A > G)

IL4RA(g.54150A>G)

IL1B(−31T>C)
IL1B(−511C>T)
IL1B(3953 C>T)
IL1B(c.−198T>C)
IL4RA(c.1902 A>G)
IL6(−174G>C)
IL6(−596G>A)
IL8(−251T>A)
IL10(−1082G>A)
IL12(g.19532A>C)
IL18(−607C>A)
IL18(−137G>C)
PXR(g.39403G>A)
TNF(−238G>A)
TNF(8156G>A)
TNF(−308G>A)

FUT223, 24

FUT2 (428G>A)

Antioxidants25, 26

HMOX1(p.D7H)
GCLC(g.−129 C>T)
SOD2(p.A16V)
GSTP1(p.I1047V)
NQO1(p.P187S)
NFE2L2(−617C>A)
CYBA(C242T)

Author Manuscript

Vascular homeostasis22, 27–29

VEGF(C-2578A)
eNOS(894G>T)
eNOS(−786T>C)

VEGF(T-460C)
VEGF(+405C)
CPS1(p.Thr1406Asn)
END-1 (5665G>T)

HB-EGF30

HBEGF(140338940G>T)

HBEGF(140333293G>A) HBEGF(140334979C>T)
HBEGF(140337403G>C) HBEGF(140347675G>A)

Genes listed as gene name (SNP or amino acid change).
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**

Increased risk for NEC reported when more than 2 NOD2 variants are present.

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
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Table 2:

Author Manuscript

Characteristics of included studies.
Study
Trezl

200118
200219

Country

Number of cases/controls

Definition of NEC cases

Functional studies

Validation cohort

Hungary

46/90

Included Bell Stage I

No

No

Hungary

46/90

Included Bell Stage I

No

No

Treszl

200317

Hungary

46/90

Included Bell Stage I

No

No

Zouali

200512

Heninger

France

10/103

Unclear

No

No

Szebani

20068

Hungary

41/77

Included Bell Stage I

No

No

Banyasz

200629

Hungary

49/79

Included Bell Stage I

No

No

Moonen

200727

Netherlands

17/34

≥ Bell Stage II

No

No

No

No

200720

Australia

50/50

Included Bell Stage I

Sampath

20119

USA

15/255

Included Bell Stage I

No

No

Morrow

201123

USA

30/410

≥ Bell Stage II

Yes

No

Prencipe 201215

Italy

41/66

≥ Bell Stage II

Yes

No

Sankararaman 201316

USA

36/534

Included Bell Stage I

No

No

Zhou 201510

China

42/83

≥ Bell Stage II

No

No

Franklin 201521

USA

66/118

≥ Bell Stage 2

No

No

Sampath 201511

USA

17/20

≥ Bell Stage II

Yes

No

Sampath 201525

USA

52/585

≥ Bell Stage II

No

No

Demmert 201524

Germany

108/2406

Included SIP and Surgical
NEC

No

No

Hartel 201613

Germany

262/6680

Included SIP and ≥ Bell
Stage II

No

No

Moonen 201628

Netherlands

36/441

≥ Bell Stage II

No

Yes

201748

China

102/120

≥ Bell Stage II

No

No

Netherlands

28/392

≥ Bell Stage II

No

No

Henderson

Author Manuscript
Author Manuscript

Tian

Huizing

201726
201714

USA

86/929

Included Bell Stage I

No

Yes

201830

China

30/80

≥ Bell Stage II

Yes

No

Szpecht 201822

Poland

22/78

Included Bell Stage I

No

No

USA

30/721

Surgical NEC

No

Yes

Sampath
Ma

Jilling 201857
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